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Background: The introduction of high-risk human papillomavirus (hrHPV) testing as part of primary cervical
screening is anticipated to improve sensitivity, but also the number of women who will screen positive.
Reflex cytology is the preferred triage test in most settings but has limitations including moderate diagnostic
accuracy, lack of automation, inter-observer variability and the need for clinician-collected sample. Novel,
objective and cost-effective approaches are needed.
Methods: In this study, we assessed the potential use of an automated metabolomic robotic platform,
employing the principle of laser-assisted Rapid Evaporative Ionisation Mass Spectrometry (LA-REIMS) in cer-
vical cancer screening.
Findings: In a population of 130 women, LA-REIMS achieved 94% sensitivity and 83% specificity (AUC: 91.6%)
in distinguishing women testing positive (n = 65) or negative (n = 65) for hrHPV. We performed further anal-
ysis according to disease severity with LA-REIMS achieving sensitivity and specificity of 91% and 73% respec-
tively (AUC: 86.7%) in discriminating normal from high-grade pre-invasive disease.
Interpretation: This automated high-throughput technology holds promise as a low-cost and rapid test for
cervical cancer screening and triage. The use of platforms like LA-REIMS has the potential to further improve
the accuracy and efficiency of the current national screening programme.
Funding: Work was funded by the MRC Imperial Confidence in Concept Scheme, Imperial College Healthcare
Charity, British Society for Colposcopy and Cervical Pathology, National Research Development and Innova-
tion Office of Hungary, Waters corporation and NIHR BRC.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/)Keywords:
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Cervical cancer is largely preventable through treatment of
screen-detected cervical lesions. It has a long natural history with a
prolonged precancerous phase that is easily detectable and treatable.
Exfoliative cytology has been the mainstay for screening of cervical
pre-invasive disease (cervical intraepithelial neoplasia or CIN) for
almost half a century. HPV testing that detects the presence of high-risk oncogenic HPV (hrHPV) infection is replacing cytology in primary
screening programmes. This has been found to have superior perfor-
mance to that of cytology in the detection of high-grade CIN with bet-
ter sensitivity and negative predictive value and can provide 6070%
greater protection against cervical cancer in women over the age of
30 1-3. Moreover, hrHPV testing is objective, automated and user-
independent 4. However, hrHPV testing has a low specificity and tri-
age tests are required to select HPV positive women that should be
referred to colposcopy to minimise overburdening of clinical services.
Although a number of tests are under investigation, currently cytol-
ogy is preferred as the test of choice for triage in most settings.
Despite the obvious advantages of HPV testing as a primary
screening test, this is costly. Furthermore, triage cytology for hrHPV
Research in context
Evidence before this study
Human papillomavirus (HPV)-based screening has improved
sensitivity compared to cytology and has replaced cytology in
primary cervical screening. HPV-based screening is expected to
increase the number of women that will test positive at screen-
ing due to low specificity. Currently, reflex cytology is the single
validated triage test in the UK for referral to colposcopy,
although this has demonstrated only moderate sensitivity and
specificity. Furthermore, triage cytology lacks automation, is
lengthy, prone to human error and is of low sensitivity. Given
the high prevalence of passenger HPV infections with no carci-
nogenic potential and the mediocre performance of most exist-
ing triage tests, novel technologies that offer rapid, cost-
afforded and simultaneous HPV testing and automated triaging
of women at high risk of high-grade precancer are highly
sought after.
Added value of this study: In this proof-of concept study,
we have tested the use of an innovative high-throughput ambi-
ent platform, Laser-assisted Rapid Evaporative Ionisation Mass
Spectrometry (LA-REIMS) in the cell pellets from liquid-based
cytology samples. The results suggest that LA-REIMS can rap-
idly discriminate hrHPV positive from negative samples with
good accuracy (94% sensitivity, 83% specificity) when compared
to currently validated hrHPV tests. Furthermore, it can discrimi-
nate normal from high-grade pre-invasive precancerous cells
with 91% sensitivity.
Implications of all the available evidence: If larger cohort
and biobank studies prove high performance, this technology
could offer a single, cost-effective, automated and rapid test for
cervical cancer screening, obviating the need for separate
screening and triage tests.
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prone to human error and is of low sensitivity 5-7. Given the high
prevalence of passenger HPV infections with no carcinogenic poten-
tial and the mediocre performance of most existing triage tests, novel
technologies that offer rapid, affordable and simultaneous HPV test-
ing and automated triaging of women at high risk of high-grade CIN
are highly sought after.
Metabolomics involves the detailed investigation of metabolites
and small-molecules, which are closely linked to phenotype and can
therefore be used to evaluate the health status of a patient 8. It has
been widely used to study cancer metabolism and identify bio-
markers indicative of disease states and underlying aetiology. In the
context of cervical cancer and pre-cancer, multiple platforms such as
liquid chromatography-mass spectrometry (LC-MS) 9-13, gas chroma-
tography-mass spectrometry (GCMS) 14, matrix-assisted laser
desorption ionisation (MALDI)15 and nuclear magnetic resonance
(NMR) spectroscopy 16 have shown diagnostic potential. However,
these methods tend to be laborious, requiring extensive sample prep-
aration or the use of chromatographic techniques prior to mass spec-
trometry analysis, which prevent their wide use in a clinical setting.
Ambient ionisation mass spectrometry has revolutionised the way
metabolomic experiments can be performed as it provides molecular
information for a sample in near real-time, without the need for prior
sample preparation steps 17. Ambient ionisation mass spectrometry
has been successfully used for identification of metabolite features
that permit diagnosis of different cancers in a variety of tissue types
including breast 18, liver 19, prostate 20, kidney 21 or brain cancers 22.
Rapid Evaporative Ionisation Mass Spectrometry (REIMS), includedunder the “umbrella” term of ambient ionisation techniques, employs
commonly-used surgical methods, such as standard electrosurgery or
infrared laser surgery, to cause sample evaporation and generate
information-rich gas-phase ions 23. The tissue-derived smoke that is
created from the rapid heating contains information about the phos-
pholipid signature of the tissue which can be used for accurate dis-
crimination of tissue types as well as real-time, intraoperative
detection of cancer or evaluation of surgical margins 24-26. We have
also recently shown that REIMS coupled to electrosurgery via a hand-
held device (also known as the intelligent knife  iKnife) permits
detection of precancerous lesions and cervical cancer with high diag-
nostic accuracy 27.
In order to minimize the user input and facilitate clinical imple-
mentation, REIMS has been more recently developed into a high-
throughput and automated platform to replace the previous hand-
held technology. The laser-assisted REIMS (LA-REIMS) setting has
been used with success for different applications, such as direct-
from-culture identification of bacteria 28 or yeast 29. A more recent
study has also employed LA-REIMS for the diagnosis of Type 2 diabe-
tes in faecal samples 30.
In this study, we first evaluated the ability of LA-REIMS to distin-
guish women with hrHPV infections from those without via analysis
of cell pellets recovered from liquid-based cytology (LBC) samples.
Further, we aimed to evaluate whether this technology could also
detect women with high-grade precancerous cytology.
2. Materials and methods
2.1. Population  inclusion and exclusion criteria
We prospectively recruited non-pregnant women that attended
the colposcopy and gynaecology clinics at Imperial College NHS
Healthcare Trust between 2015 and 2018. We recruited a cohort of
65 hrHPV positive women and similar size population of 65 consecu-
tive controls that had tested negative for hrHPV. We included women
irrespective of age, parity, ethnicity, smoking habits, the use of con-
traception and menopause status. We excluded pregnant women
and women who were HIV positive. Detailed medical and gynaeco-
logical history was collected including time since last sexual inter-
course and douching practices. Ethnicity was self-reported as
Caucasian, Asian, Black or mixed (Afro-Caribbean/Irish; White Afri-
can; Afro-Caribbean/British). All women gave written consent (REC
Fulham: 13/LO/0126).
2.2. Sample collection and preparation
From women participating, we collected a liquid-based cytology
(LBC) sample of exfoliated cells using a disposable speculum and a
cytobrush; the brush was then suspended into the methanol-based
preservative solution (ThinPrep, HOLOGIC Inc., USA) and vigorously
swirled to release the cytological material and stored at 4 °C until fur-
ther analysis. The sample was collected without the use of lubrication
and prior to the application of acetic acid or iodine. High-risk HPV
(hrHPV) detection was performed on the collected samples to iden-
tify 14 hrHPV subtypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
66 and 68) using clinically validated hrHPV assays. A brief overview
of the method workflow, depicting the steps from sample collection
and preparation to spectral generation and classification, is provided
in Fig. 1.
From the remaining LBC solution, 2 ml were aliquoted in pre-
weighted microcentrifuge tubes and randomised. All samples were
prepared and analysed at the same time. The researcher conducting
the experiments was blinded to the class of the samples during anal-
ysis. Samples were centrifuged at 21,000xg for 5 mins and superna-
tant was removed. Sterile water was used for three sequential
washes of the cell pellet, with the supernatant being removed after
Fig. 1. Experimental workflow. (a) Liquid-based cytology (LBC) samples are collected and aliquoted for subsequent analyses. (b) High-risk (hr) HPV detection along with histologi-
cal, if clinically indicated, and/or cytological diagnosis are performed. (c) LA-REIMS high-throughput analysis is performed, and raw spectral information is collected and pre-proc-
essed. (d) Analysis of mass spectrometry data is conducted using machine learning approaches. (e) The technique’s performance for differentiation and classification of the different
cohorts is assessed.
M. Paraskevaidi et al. / EBioMedicine 60 (2020) 103017 3each centrifuge cycle. The weight of the cell pellet from each sample
was recorded prior to analysis with LA-REIMS to ensure the presence
of adequate cellular material (>10 mg); cell counting was not feasible
in the cell pellet due to the destructive nature of the technique.
2.3. High-throughput LA-REIMS analysis
Pellets of samples were then placed into the high-throughput,
commercially available robotic Freedom Evo 75 platform (TECAN,
Switzerland) for analysis. A helium gas-cooled CO2 surgical laser
(FELS-25A, OmniGuide, USA), with a fibre optic beam guide, wave-
length of 10.6 mm and 30 psi gas pressure, was utilised with a power
setting of 1.5 W in SuperPulse pulsatile mode with 40 ms pulse win-
dows. The resulting analyte-containing vapour was transferred for
mass spectrometry analysis through PTFE tubing to a Xevo G2-XS Q-
ToF (Waters Corporation, UK) operated under conditions given in
Supp Table S1. Prior to entry into the mass spectrometer, the gener-
ated vapour was mixed with 2-propanol containing leucine encepha-
lin at a concentration of 0.1 ng/mL, at a flow rate of 0.2 mL per
minute. We performed quality control measurements by infusing
continuously leucine enkephalin to 2-propanol ionisation matrix that
was within an acceptable range; there was no significant difference
between the compared groups based on HPV infection and disease
severity (Supp Fig. 1). The resulting mixture passed through the
REIMS atmospheric interface chamber where solvention clusters
collide with a heated (700800 °C) coil before entry into the
StepWave of the MS instrument 31 (Fig. 2). The instrument was cali-
brated daily using sodium formate in negative ionisation mode, fol-
lowing the manufacturer’s standard instructions. Mass spectrometry
analysis was performed in full scan, negative ionisation mode with
mass spectra acquired over the 50 to 1200 m/z range. Representative
spectra across the mass range of 501000 m/z and 600850 m/z are
shown in Supp Fig. 2. The required analysis time for running 24 sam-
ples was approximately 10 min.2.4. Data and statistical analysis
For the primary analysis, women were classified into two groups:
hrHPV positive and negative. We used the resulting spectral data to
explore whether LA-REIMS was able to distinguish women with and
without a high-risk HPV infection. We calculated accuracy parame-
ters that included sensitivity, specificity and the area under the curve
(AUC). Furthermore, we performed additional analysis to explore
whether the LA-REIMS had the ability to discriminate women with-
out precancerous changes (normal/HPV) from women with clinically
significant disease (CIN2 or worse). We chose this comparison as the
most clinically relevant outcome for our main analysis. We per-
formed a series of secondary analysis exploring different compari-
sons and calculated accuracy parameters for different comparisons.
We performed further subgroup analyses using as gold standard his-
tology alone. Finally, we explored the accuracy of LA-REIMS in dis-
criminating normal/HPV from CIN2 or worse as per the main analysis
but restricting these to hrHPV positive women in an attempt to
mimic the current screening algorithms that uses cytology as a reflex
test.
We used histology in preference to cytology to define the disease
grade. If histology was present from a punch biopsy and a cone docu-
menting different grade, the most severe lesion was considered. If
histology was not available as not clinically indicated (negative or
borderline cytology), cytology was used for classification. Cytological
and histological assessments were performed by experienced cytopa-
thologists.
To assess whether there were any potential baseline differences in
selected clinical and demographic characteristics, we performed sta-
tistical analysis using IBM SPSS Statistics (version 26). P values were
calculated using a t-test or one-way ANOVA test for the age and a
Fisher’s exact test for hrHPV status, disease status, ethnicity, parity,
smoking, contraception and menopause. A P value< 0.05 was consid-
ered significant.
Fig. 2. LA-REIMS experimental setting (adapted from Cameron et al. 31 and Gowers et al. 29).
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underwent pre-processing with the Offline Model Builder (OMB)
software (version 1.1.29.0, Waters) to perform background sub-
traction and mass drift correction against leucine encephalin lock
mass compound (negative ionisation mode m/z = 554.2615). Fol-
lowing background subtraction and lockmass correction, spectra
were normalised based on total ion count and re-binned to
0.1 Da within the 50 to 1200 m/z range. After pre-processing of
the mass spectra with the OMB software, filtering for signal-to-
noise ratios was completed to identify samples with insufficient
cellular material for analysis. This was completed by calculating
the average for each of the top ten most intense features in the
mass spectra and identifying those samples that were below a
single standard deviation in at least three of the features. After
sample filtering, a data matrix was exported and uploaded on the
MetaboAnalyst 4.0 online platform 32, where additional process-
ing was performed for data filtering (mean intensity value), log
transformation and Pareto Scaling (mean-centred and divided by
the square root of the standard deviation of each variable) prior
multivariate analysis. Spectra were further interrogated within
the 6001000 m/z range.
Random forest algorithms were used as a machine learning
approach for sample classification and evaluation of the technique’s
performance. Random forest models allow prediction of unknown
samples (i.e. test dataset) after training on a known dataset (i.e. train
dataset). Receiver operating characteristic (ROC) curves were gener-
ated by Monte-Carlo cross validation (MCCV) using balanced sub-
sampling. This method is a cross validation approach which creates
multiple random splits of the dataset into training and validation
data 33. For each split, the model is fit to the training data and predic-
tive accuracy is assessed using the validation data. The results are
then averaged over the splits. In each MCCV, two thirds (2/3) of thesamples were used as the training dataset and the performance of
the model was then validated on the one third (1/3) of the samples
that were left out, used as the test dataset 34.
To tentatively assign the mass spectral features that were most
responsible for the observed differentiation, we performed univariate
analysis using a volcano plot, which is a combination of fold change
and t-tests, (fold change threshold=2; FDR adjusted P value with 0.05
threshold). After background removal and mass drift correction in
MassLynx software (version 4.1, Waters Corporation), significant
mass bins were interrogated to identify peaks within these mass bins
with a mass accuracy of two decimal places. The exact mass measures
were subsequently used to interrogate the LIPID MAPS database 35
and the Human Metabolome Database (HMDB) 36, allowing for a
mass tolerance of §0.01 m/z, with the highest ranked match being
based on the Delta value.
3. Results
We recruited a total of 145 women; 15 were removed from fur-
ther analysis due to insufficient cellular material (cell pellet weight
<10 mg) and/or low signal-to-noise ratio (Fig. 3). Of the remaining
130 women included in the final analysis, half were hrHPV positive
(n = 65) and half hrHPV negative (n = 65) as determined using clini-
cally approved hrHPV assays. The main patient characteristics and
demographics of the two patient populations are shown in Table 1.
Out of the 65 women positive for hrHPV, 20 (30.8%) had HPV16 only,
3 (4.6%) had HPV18 only, 15 (23.1%) had HPV16 and other hrHPV, 11
(16.9%) had HPV16/18 with or without other hrHPV and 16 (24.6%)
had other than 16/18 hrHPV subtypes. The two groups had similar
mean age (36.6y for hrHPV positive vs 34.3y for hrHPV negative
women) (P value=0.139, t-test), with the majority being Caucasian in
both groups (86 vs 78%) (P value=0.077, Fisher’s exact test) and
Fig. 3. Recruited population - 145 women; 130 eligible for analysis. HPV status: 65
positive  65 negative. Disease status: Normal = 49 (confirmed by histology (n = 32) or
cytology (n = 17)), HPV = 6, CIN1 = 30, CIN2 = 23, CIN3 = 17 and Cancer = 5. All apart
from some normal had histological confirmation of disease status. hrHPV=high-risk
human papillomavirus; CIN=cervical intraepithelial neoplasia
Table 1
Patient characteristics of women according to their HPV status (hrHPV+ or hrHPV-). P
values were calculated using a t-test for the age and a Fisher’s exact test for disease sta-
tus, ethnicity, parity, smoking, contraception andmenopause. A P value< 0.05 was con-
sidered significant.
Patient Characteristics hrHPV+ (N = 65) hrHPV- (N = 65) P value
Age
Mean (SD, range) 36.6 (9.9, 2569) 34.3 (7.9, 2364) 0.139
Disease Status, n/N (%) <0.0001
Normal* /HPV 12/65 (18.5) 43/65 (66.2)
CIN1 13/65 (20.0) 17/65 (26.1)
CIN2 21/65 (32.3) 2/65 (3.1)
CIN3 14/65 (21.5) 3/65 (4.6)
Cancer 5/65 (7.7) 0/65 (0.0)
Ethnicity, n/N (%) 0.077
Caucasian 56/65 (86.2) 51/65 (78.5)
Asian 6/65 (9.2) 3/65 (4.6)
Black 3/65 (4.6) 7/65 (10.8)
Mixed** 0/65 (0.0) 4/65 (6.1)
Parity, n/N (%) 1.000
Nulliparous 46/65 (70.8) 48/65 (73.9)
Parous 16/65 (24.6) 17/65 (26.1)
Unknown 3/65 (4.6) 0/65 (0.0)
Smoking Status, n/N (%) 0.302
Current smoker 18/65 (27.7) 13/65 (20.0)
Non/Ex-smoker 44/65 (67.7) 52/65 (80.0)
Unknown 3/65 (4.6) 0/65 (0.0)
Contraception, n/N (%) 0.653
Nil 24/65 (36.9) 28/65 (43.1)
Condoms 12/65 (18.5) 11/65 (16.9)
COCP/POP 16/65 (24.6) 14/65 (21.5)
IUCD/IUD/Mirena/Con-
traceptive (injection/
depot/implant/patch)
6/65 (9.2) 11/65 (16.9)
Unknown 7/65 (10.8) 1/65 (1.6)
Menopause, n/N (%) 0.719
Pre-menopausal 60/65 (92.3) 57/65 (87.7)
Post-menopausal 5/65 (7.7) 3/65 (4.6)
Unknown 0/65 (0.0) 5/65 (7.7)
* Normal includes: diagnosis confirmed after histology (n = 32) and cytology (n = 17).
** Mixed includes: Afro-Caribbean/Irish; White African; Afro-Caribbean/British.
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smokers (28 vs 20%) (P value=0.302, Fisher’s exact test) and premeno-
pausal women (92 vs 88%) (P value=0.719, Fisher’s exact test) was
higher in the HPV positive group, although the differences were not
significant.
Patient characteristics according to disease status were also exam-
ined (Supp Table 2). We included women in the following groups:
normal (n = 49), HPV (n = 6), CIN1 (n = 30), CIN2 (n = 23), CIN3
(n = 17) and cancer (n = 5) (Fig. 3). All women had histological confir-
mation of disease apart from 17 women in the normal controls where
cytology defined them as normal controls.
3.1. LA-REIMS classification according to high-risk HPV status
The experimental workflow is depicted in Fig. 1. We initially
employed multivariate exploratory analysis to assess the diagnostic
performance of the automated LA-REIMS platform in distinguishing
hrHPV positive from negative women. Fig. 4 shows the classification
results after random forest analysis; the receiver operating character-
istic (ROC) curve of the best-performing model indicated an area
under the curve (AUC) of 0.916 (95% confidence interval CI: 0.859% to
0.976%) (Fig. 4a). The scores plot (Fig. 4b) shows the predicted class
probabilities for all samples included in the analysis, indicatingcorrect classification of 61 hrHPV positive and 54 hrHPV negative
samples (Fig. 4c). LA-REIMS was able to correctly classify 61 out of 65
hrHPV positive and 54 out of 65 hrHPV negative women, achieving a
94% sensitivity and 83% specificity.
Significant and important spectral features that were responsible
for the observed differentiation between the two classes were found
after univariate analysis and tentatively assigned using online data-
bases (Fig. 5, Supp Table S3). More specifically the following features
were found significantly different in our cohort: m/z 670.53 (Hexosyl
ceramide (HexCer(d32:1)), m/z 674.48 (phosphoethanolamine (PE
(31:1)),m/z 681.55 (diglyceride DG(40:6)) andm/z 746.57 (PE(36:0)).
3.2. LA-REIMS classification according to cervical disease severity
Our secondary analysis aimed to investigate the ability of LA-
REIMS to distinguish women with CIN2 or worse (CIN2+) (n = 45)
from normal controls without preinvasive disease (normal  HPV)
(n = 55) (Fig. 6), which was considered the most clinically relevant
outcome of the main patient groups. After ROC analysis, the achieved
AUC was 0.867 (95% CI 0.7460.947), denoting a satisfactory diagnos-
tic accuracy and trade-off between sensitivity and specificity (Fig. 6a).
From the plot of predicted class probabilities (Fig. 6b), it is evident
that LA-REIMS was able to correctly classify 41 out of 45 CIN2+
lesions and 40 out of 55 normal controls, allowing for 91% sensitivity
and 73% specificity (Fig. 6c).
Additional analyses exploring comparisons of different groups of
disease status indicated again that the diagnostic accuracy of LA-
REIMS was comparable or even superior to that of reflex cytology
Fig. 4. LA-REIMS classification according to hrHPV status. (a) Receiver operating characteristic (ROC) curve after employing random forest as the classification method. The gener-
ated values for the area under the curve (AUC) along with 95% confidence intervals (CI) are given within the plot. (b) Predicted class probabilities for each sample allowing visualisa-
tion of the misclassified samples (hrHPV+ shown as black dots; hrHPV shown as white dots). As a balanced subsampling approach is used for model training, the classification
boundary is always at the centre (x = 0.5, the dotted line). (c) Confusion matrix showing the number of true positives (61/65), true negatives (54/65), false positives (11/65) and false
negatives (4/65). Sensitivity and specificity are given in the green-highlighted regions, being 94% and 83% respectively.hrHPV: high-risk human papillomavirus
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gold standard histology alone in a cohort of 117 women. The results
were consistently good: ie. Normal/HPV (n = 38) versus CIN2+
(n = 45): 85% sensitivity and 66% specificity. Finally, we explored the
accuracy of LA-REIMS in discriminating normal/HPV from CIN2 or
worse as per the main analysis but restricting these to hrHPV positive
women (n = 65) in an attempt to mimic the current screening algo-
rithms that uses cytology as a reflex test. This showed good discrimi-
nation (normal/HPV (n = 12) versus CIN2+ (n = 40): 70% sensitivity
and 75% specificity.
4. Discussion
The introduction of hrHPV in primary screening is expected to
lead to new challenges for national screening programmes across the
globe. HrHPV test is replacing cytology as a primary screening test in
the UK, with reflex triage cytology being used to determine women
that need referral to colposcopy 6,37,38. HrHPV test is anticipated toFig. 5. Significant mass spectral features after univariate analysis according to hrHPV status
(n = 65) and hrHPV positive (n = 65) women were selected by volcano plot with fold change
tures were provided after interrogation of the LIPID MAPS database and Human Metabolomeoffer improved sensitivity in detecting high-grade precancer and a
6070% greater protection against cervical cancer when compared to
cytology 1, but is less specific and will also increase the number of
women who screen positive. hrHPV can be costly, whilst triage cytol-
ogy is labour-intensive, not automated, subjective and has demon-
strated average sensitivity and specificity in detecting CIN2 or worse.
Although automated platforms for cytology are currently under
investigation (Hologic image-assisted screening (IAS) and Surepath
FocalPoint system), these are not widely used in clinical practice. To
date there has been no single test that has achieved both high sensi-
tivity and specificity in distinguishing women at high risk of high-
grade precancer that warrant referral to colposcopy. The identifica-
tion of innovative technologies that have the potential to offer pri-
mary screening and triage of screen-positive women in a single
rapid, low cost test that would determine women with transient HPV
infection from those that may harbour high-grade pre-invasive
remains one of the most significant challenges in the reorganisation
of the services in primary cervical screening (Supp Fig 3).. Important features responsible for the observed segregation between hrHPV negative
threshold = 2 and FDR adjusted P value = 0.05. Tentative assignments of important fea-
Database (HMDB) (Supp Table S3).
Fig. 6. LA-REIMS classification according to cervical disease severity. (a) Receiver operating characteristic (ROC) curve after employing random forest as the classification method.
The generated values for the area under the curve (AUC) along with 95% confidence intervals (CI) are given within the plot. (b) Predicted class probabilities for each sample allowing
visualisation of the misclassified samples (CIN2+ shown as black dots; normal controls shown as white dots). As a balanced subsampling approach is used for model training, the
classification boundary is always at the centre (x = 0.5, the dotted line). (c) Confusion matrix showing the number of true positives (41/45), true negatives (40/55), false positives
(15/55) and false negatives (4/45). Sensitivity and specificity are given in the green-highlighted regions, being 91% and 73% respectively.CIN: cervical intraepithelial neoplasia; HPV:
human papillomavirus.
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analysis of LBC derived cell pellets can be used to distinguish women
with or without a hrHPV infection with high diagnostic accuracy
(94% sensitivity and 83% specificity). The emphasis of primary popu-
lation-based screening is high sensitivity with low false negative rate
in order not to miss disease. Our results using the LA-REIMS platform
show promise as these preliminary findings document comparable
accuracy to other clinically validated molecular HPV tests used for
screening 39-42, but possibly at significantly lower cost (£1.60/sam-
ple).
Deregulated lipid metabolism has long been recognised to play an
important role in carcinogenesis 43. An increased rate of lipid synthe-
sis has been previously described in cancerous samples in compari-
son to normal controls 43,44, rendering these small molecules
promising diagnostic biomarkers. Changes in the lipid content have
also been utilised as indicators of tumour progression and metastasis
45,46. The observed lipid alterations reflect structural and functional
modifications of the cell membrane which occur during carcinogene-
sis. Ambient ionisation mass spectrometry techniques favour the
detection of small metabolites, such as fatty acids or more complex
lipids  a field known as lipidomics 47,48. The use of REIMS, specifi-
cally, allows interrogation of the phospholipid signature of a biologi-
cal sample, which can be subsequently used towards sample
identification. REIMS has been previously employed to allow discrim-
ination between healthy and malignant cases based on differences in
the relative intensities and distribution of phospholipids 24-26.
The satisfactory segregation achieved in the current study
between women with and without hrHPV infection may be attrib-
uted to differential lipid expression due to the viral infection or an
altered microbiome associated to HPV. In this study we attempted to
tentatively assign discriminatory spectral features, however confir-
mation of these pilot signatures should be performed in future stud-
ies using tandem mass spectrometry. Indeed, infection with HPV has
been previously shown to interfere and dysregulate lipid metabolism.
In a recent LC-MS study by Ilhan et al. 49, HPV-infected individuals
were effectively distinguished from HPV-negative women based on
perturbations in membrane lipids, which generated characteristic
metabolic signatures. A different study, employing a mass spectrome-
try-based assay for cervical tissue analysis, achieved satisfactory
detection of HPV infections in ~80% of the population 50. Moreover, a
number of previous studies have demonstrated an altered bacterialmicrobiome in HPV positive women 51-53, which could also be
reflected in our results.
It is known that HPV infection can cause chronic genital inflam-
mation 54 and some of the tentatively identified lipids in this study,
including sphingolipids and phospholipids, have been previously
found to correlate with genital inflammation 49. In this previous
study by Ilhan et al. 49, relative levels of some phospholipids, such as
PE, were shown to decrease in an HPV positive cohort when com-
pared to HPV negative women but the differences were not statisti-
cally significant. A lipidomic study by Hung et al. 55 studying HPV in
cervical cancer, also demonstrated differentiation of sphingolipids
and phospholipids amongst women with different hrHPV subtypes
(altered levels in HPV18 when compared to HPV16 infected women),
which shows that HPV infection can alter these metabolites’ levels.
Application of mass spectrometry has been successful in molecu-
lar diagnostics of microbial and viral infections 56-58 as well as meta-
bolic disorders, such as Type 2 diabetes 30. Using a REIMS platform,
previous studies have detected clinically important bacteria and
fungi. More specifically, Cameron et al., reported the ability of REIMS
to rapidly identify 153 clinical Candida isolates, allowing 100% correct
species classification 59. Another study from the same group demon-
strated the ability of this setting to characterise clinically important
microorganisms from 375 isolates comprising 25 bacterial and fungal
species with an overall accuracy of 93.9% 60. More recently, a similar
laser-assisted REIMS approach using a handheld laser was used for
direct metabolomic analysis of human faecal samples allowing the
detection of microbiome-level differences 31. The LA-REIMS technol-
ogy has also been used for metabolic phenotyping of individuals with
Type 2 diabetes or euglycaemia in faeces, achieving a classification
accuracy of 90.5% (89.5% sensitivity and 91.7% specificity) and further
highlighting the potential of LA-REIMS for rapid screening and diag-
nosis of disease 30.
As a secondary objective, we assessed the technique’s ability to
distinguish women according to disease severity based on their spec-
tral information. The sensitivity and specificity achieved for high-
grade lesions or worse (CIN2+) were ~90% and ~70% respectively.
Reflex cytology has been reported to achieve pooled sensitivity and
specificity of 71% and 73% for detection of CIN2+ 61, although this
varies across different settings and depends on the quality and per-
formance of cytology (sensitivity ranging between 63 and 71% and
specificity 7389% across studies) 61-63. Furthermore, Arbyn et al. 64
8 M. Paraskevaidi et al. / EBioMedicine 60 (2020) 103017reported that from hrHPV positive women at screening, 56% had ASC-
US (atypical squamous cells of undetermined significance) or worse
cytology (1604/2882), of whom 612 were found to have CIN3+, corre-
sponding to a positive predictive value (PPV) of 38%. Despite the
expected improved accuracy for cytology as a triage test when com-
pared to its performance as screening test given the highest preva-
lence of the disease 65, the sensitivity and specificity is still average.
As such, LA-REIMS has the potential to be tested against reflex cytol-
ogy, the currently preferred triage test in most settings, in future
non-inferiority clinical trials.
We chose the classification between normal/HPV versus CIN2+ as
the most clinically relevant discrimination for the main analysis and
performed a series of alternative comparisons. All confirmed high
accuracy in LA-REIMS in discriminating correctly women in each
group. When the analysis was restricted to samples with histological
confirmation, the results were consistently good. We further mim-
icked current triage protocols and assessed the ability of LA-REIMS to
detect disease state in hrHPV positive women alone with good dis-
crimination, although the sample size was small. A number of hrHPV
negative women had precancerous changes in cytology. Classification
of cytology in the subgroup of HPV negative women was not per-
formed given the lack of clinical significance of cytology changes in
hrHPV negative samples within current screening programmes.
A number of mass spectrometry studies have previously reported
satisfactory diagnostic accuracy of cervical cancer or pre-cancer,
however these were performed either on cervical tissue samples 27,
rendering it unsuitable as a screening approach, or using more labori-
ous and time-consuming approaches 9,11-13. Different studies
employing vibrational spectroscopic approaches, including Raman
and infrared spectroscopy, have demonstrated the ability of detecting
biological differences between normal, precancerous and cancerous
cervical pathologies using cytology samples 66,67. Although previous
studies have explored the effectiveness LA-REIMS as a new platform
of ambient mass spectrometry 29-31,60, this has not been tested in the
cervix. To our knowledge, this is the first study of its kind, to deter-
mine the use of the robotic, ambient LA-REIMS platform as a means
to analyse non-invasively collected cell pellets towards a real-time
and objective test for cervical pre-cancer and cancer.
There are of course limitations. The aim of our study was to gener-
ate a spectral fingerprint that would allow segregation between the
different cohorts (HPV status and cytology). We attempted to tenta-
tively assign discriminatory spectral features. However, biomarker
discovery was beyond the scope of this study and, as such, fragmen-
tation spectra were not collected as part of this experimental run.
Future studies in larger cohorts should further explore specific bio-
markers and biochemical pathways. We used the commonly used
methanol-based LBC solution for the suspension of the cells that
required sequential washes with water for the methanol removal.
Although previous studies showed good biological preservation in
alcohol-based fixative solutions10,11,68,69, future studies should
explore methanol-free preservation media to permit development
towards a point-of-care instrument. Even though we chose a repre-
sentative cohort for this proof-of-concept study, a larger cohort study
is required to validate these results and further explore the use of the
technology as a triage tool in hrHPV positive women alone. If this
confirms high accuracy at least non-inferior to existing tests, follow-
on cohort and longitudinal case-control clinical trials nested within
existing screening programmes are required prior to implementation
in clinical services. Additionally, it should be noted that a biological
quality control (QC) was not used in this experiment. Leucine
enkephalin levels, infused into the solvent matrix with the analyte
vapour, were used to monitor the operation of the REIMS interface
and mass spectrometer. However, this is independent from the anal-
ysis of biological samples  either through a master mix of randomly
selected samples or a commercially available mixture  and means
that we did not measure the potential variation of sample heatingwithin and between batches. Although levels of leucine enkephalin
are shown to not differ significantly, a potential bias may remain in
our analysis that cannot be controlled for as a QC of biological sam-
ples was not included.
In conclusion, this is the first study to demonstrate that the auto-
mated, high-throughput LA-REIMS platform has the potential to
develop into a rapid low-cost platform for screening and triage for
cervical cancer. This approach has the advantage of providing simul-
taneous information for both the hrHPV status (determining if posi-
tive or negative for hrHPV) and disease severity (determining if
normal or high-grade precancer/cancer), and can permit the accurate
selection of screened women that should be referred for further col-
poscopic assessment with or without biopsy (for diagnosis) and those
that can safely return to routine recall with a much-reduced resource
requirement with regards to both time and cost. Such a technology
could be of particular benefit in middle- or low-income countries
given its low cost and the lack of laboratory infrastructure for cytol-
ogy reporting 70. Although LA-REIMS technology, in its present form,
could be implemented in central laboratories alone, future adaptation
of this technology into a less bulky and user-friendly system, has fur-
ther potential to permit its use into primary care as a bedside point-
of-care tool that would provide instant results minimising patient
anxiety. This technology warrants further assessment in well-
designed trials.
Data sharing statement
Raw mass spectral files have been uploaded to the Metabolights
repository (MTBLS1371).
Author contributions
The study was conceived and designed by MK, MP, SJSC and ZT.
The samples were collected by SB, MT, AM, AS, AA and MK. MP, SJSC
and EW conducted experimental work. Data analysis was performed
by MP and SJSC. The data was interpreted, and the manuscript was
drafted and revised critically for important intellectual content by all
authors. All authors gave final approval of the version to be published
and have contributed to the manuscript.
Declaration of Competing Interest
DAM has a patent EP3570315A3 issued ‘REIMS and DESI analysis
of biopsy samples'. ZT reports grants and personal fees from Waters
Corporation and has a patent US 9,709,529 issued. Other authors
declare no competing interests.
Acknowledgements
We would like to thank all the patients from Imperial College
Healthcare NHS Trust (ICHT) and tissue bank who provided their tis-
sue samples for our research project. Special thanks to the colposcopy
team at the St. Mary’s site of ICHT for their cooperation during our
recruitment and sample collection process.
Funding
This work was funded by the MRC Imperial Confidence in Concept
Scheme (PS2857, PS2897). This work was also supported by Imperial
College Healthcare Charity (RF16\10001) [MT, MK]; British Society
for Colposcopy and Cervical Pathology [MK]; National Research
Development and Innovation Office of Hungary (KNN121510,
NVKP_16-1-2016-0042) and Waters corporation (P53626_WSSB).
Waters Corporation has provided analytical instrumentation for the
study and the Imperial Experimental Cancer Medicine Centre, the
Cancer Research UK Imperial Centre, Imperial Healthcare NHS Trust
M. Paraskevaidi et al. / EBioMedicine 60 (2020) 103017 9NIHR BRC. Imperial College London receives financial support from
the National Institute of Health Research (NIHR) Imperial Biomedical
Research Centre (BRC) based at Imperial College Healthcare NHS
Trust and Imperial College London. This article is independent
research funded by the NIHR BRC, and the views expressed in this
publication are those of the authors and not necessarily those of the
NHS, NIHR, or the Department of Health. None of the funders have
had any influence over: study design, collection, analysis and inter-
pretation of the data, in writing the report and in the decisions to
submit this article for publication.Supplementary materials
Supplementary material associated with this article can be found,
in the online version, at doi:10.1016/j.ebiom.2020.103017.References
[1] Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV-based screening for preven-
tion of invasive cervical cancer: follow-up of four European randomised con-
trolled trials. Lancet 2014;383(9916):524–32.
[2] Ogilvie GS, van Niekerk D, Krajden M, et al. Effect of screening with primary cervi-
cal HPV testing vs cytology testing on high-grade cervical intraepithelial neopla-
sia at 48 months: the HPV FOCAL randomized clinical trial. JAMA 2018;320
(1):43–52.
[3] Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis
E. Diagnostic accuracy of human papillomavirus testing in primary cervical
screening: a systematic review and meta-analysis of non-randomized studies.
Gynecol Oncol 2007;104(1):232–46.
[4] Kyrgiou M, Arbyn M, Bergeron C, et al. Cervical screening: ESGO-EFC position
paper of the european society of gynecologic oncology (ESGO) and the European
federation of colposcopy (EFC). Br J Cancer 2020;8:1–8.
[5] Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American
studies on HPV testing in primary cervical cancer screening. Int J Cancer
2006;119(5) 1095-101.
[6] Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus
Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357(16):1579–88.
[7] Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and
histologic interpretations: realistic estimates from the ASCUS-LSIL triage study.
JAMA 2001;285(11):1500–5.
[8] Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease.
Cell 2008;134(5):714–7.
[9] Chen Y, Xu J, Zhang R, et al. Assessment of data pre-processing methods for LC-
MS/MS-based metabolomics of uterine cervix cancer. Analyst 2013;138(9):2669–
77.
[10] Papachristou EK, Roumeliotis TI, Chrysagi A, et al. The shotgun proteomic study of
the human ThinPrep cervical smear using iTRAQ mass-tagging and 2D LC-FT-
Orbitrap-MS: the detection of the human papillomavirus at the protein level. J
Proteome Res 2013;12(5):2078–89.
[11] Porcari AM, Negr~ao F, Tripodi GL, et al. Molecular signatures of high-grade cervi-
cal lesions. Front Oncol 2018;8:99.
[12] Yin MZ, Tan S, Li X, et al. Identification of phosphatidylcholine and lysophosphati-
dylcholine as novel biomarkers for cervical cancers in a prospective cohort study.
Tumor Biol 2016;37(4):5485–92.
[13] Yang K, Xia B, Wang W, et al. A comprehensive analysis of metabolomics and
transcriptomics in cervical cancer. Sci Rep 2017;7:43353.
[14] Woo HM, Kim KM, Choi MH, et al. Mass spectrometry based metabolomic
approaches in urinary biomarker study of women's cancers. Clin Chim Acta
2009;400(12):63–9.
[15] Liu Y, Wei F, Wang F, et al. Serum peptidome profiling analysis for the identifica-
tion of potential biomarkers in cervical intraepithelial neoplasia patients. Bio-
chem Biophys Res Commun 2015;465(3):476–80.
[16] Hasim A, Ali M, Mamtimin B, Ma JQ, Li Q-Z, Abudula A. Metabonomic signature
analysis of cervical carcinoma and precancerous lesions in women by 1H NMR
spectroscopy. Exp Ther Med 2012;3(6):945–51.
[17] Ifa DR, Eberlin LS. Ambient ionization mass spectrometry for cancer diagnosis and
surgical margin evaluation. Clin Chem 2016;62(1):111–23.
[18] Calligaris D, Caragacianu D, Liu X, et al. Application of desorption electrospray
ionization mass spectrometry imaging in breast cancer margin analysis. Proc Natl
Acad Sci USA 2014;111(42):15184–9.
[19] Golf O, Strittmatter N, Karancsi T, et al. Rapid evaporative ionization mass spec-
trometry imaging platform for direct mapping from bulk tissue and bacterial
growth media. Anal Chem 2015;87(5):2527–34.
[20] Kerian K, Jarmusch A, Pirro V, et al. Differentiation of prostate cancer from normal
tissue in radical prostatectomy specimens by desorption electrospray ionization
and touch spray ionization mass spectrometry. Analyst 2015;140(4):1090–8.
[21] Dill AL, Eberlin LS, Zheng C, et al. Multivariate statistical differentiation of renal
cell carcinomas based on lipidomic analysis by ambient ionization imaging mass
spectrometry. Anal Bioanal Chem 2010;398(78):2969–78.[22] Sch€afer K-C, Balog J, Szaniszlo T, et al. Real time analysis of brain tissue by direct
combination of ultrasonic surgical aspiration and sonic spray mass spectrometry.
Anal Chem 2011;83(20):7729–35.
[23] Takats Z, Strittmatter N, McKenzie J. Ambient mass spectrometry in cancer
research. Adv Cancer Res 2017:231–56.
[24] Balog J, Sasi-Szabo L, Kinross J, et al. Intraoperative tissue identification using
rapid evaporative ionization mass spectrometry. Sci Transl Med 2013;5(194)
194ra93-ra93.
[25] St John ER, Balog J, McKenzie JS, et al. Rapid evaporative ionisation mass spec-
trometry of electrosurgical vapours for the identification of breast pathology:
towards an intelligent knife for breast cancer surgery. Breast Cancer Res 2017;19
(1):59.
[26] Phelps DL, Balog J, Gildea LF, et al. The surgical intelligent knife distinguishes nor-
mal, borderline and malignant gynaecological tissues using rapid evaporative
ionisation mass spectrometry (REIMS). Br J Cancer 2018;118(10):1349–58.
[27] Tzafetas M, Mitra A, Paraskevaidi M, et al. The intelligent-Knife (i-Knife) and its
intraoperative diagnostic advantage for the treatment of cervical disease. Proc
Natl Acad Sci USA 2020;117(13):7338–46.
[28] Cameron SJ, Bodai Z, Temelkuran B, et al. Utilisation of ambient laser desorption
ionisation mass spectrometry (ALDI-MS) improves lipid-based microbial species
level identification. Sci Rep 2019;9(1):3006.
[29] Gowers GOF, Cameron SJS, Perdones-Montero A, et al. Off-colony screening of
biosynthetic libraries by rapid laser-enabled mass spectrometry. ACS Synth Biol
2019;8(11):2566–75.
[30] Van Meulebroek L, Cameron S, Plekhova V, et al. Rapid LA-REIMS and comprehen-
sive UHPLC-HRMS for metabolic phenotyping of feces. Talanta 2020:121043.
[31] Cameron SJ, Alexander JL, Bolt F, et al. Evaluation of direct from sample metabolo-
mics of human feces using rapid evaporative ionization mass spectrometry. Anal
Chem 2019;91(21):13448–57.
[32] Chong J, Soufan O, Li C, et al. MetaboAnalyst 4.0: towards more transparent and
integrative metabolomics analysis. Nucleic Acids Res 2018;46(W1):W486–W94.
[33] Xu QS, Liang YZ. Monte Carlo cross validation. Chemometr Intell Lab Syst 2001;56
(1):1–11.
[34] Xia J, Wishart DS. Using MetaboAnalyst 3.0 for comprehensive metabolomics data
analysis. Curr Protoc Bioinf 2016;55(1) 14.0. 1-.0. 91.
[35] Fahy E, Subramaniam S, Murphy RC, et al. Update of the LIPID MAPS comprehen-
sive classification system for lipids. J Lipid Res 2009;50(Supplement):S9–S14.
[36] Wishart DS, Jewison T, Guo AC, et al. HMDB 3.0—The human metabolome data-
base in 2013. Nucleic Acids Res 2012;41(D1):D801–D7.
[37] Rebolj M, Rimmer J, Denton K, et al. Primary cervical screening with high risk
human papillomavirus testing: observational study. BMJ 2019;364:l240.
[38] Lew JB, Simms KT, Smith MA, et al. Primary HPV testing versus cytology-based
cervical screening in women in Australia vaccinated for HPV and unvaccinated:
effectiveness and economic assessment for the National Cervical Screening Pro-
gram. Lancet Glob Health 2017;2(2):e96–e107.
[39] Wu R, Belinson SE, Du H, et al. Human papillomavirus messenger RNA assay for
cervical cancer screening: the Shenzhen cervical cancer screening trial I. Int J
Gynecol Cancer 2010;20(8):1411–4.
[40] Ratnam S, Coutlee F, Fontaine D, et al. Aptima HPV E6/E7 mRNA test is as sensitive
as hybrid capture 2 assay but more specific at detecting cervical precancer and
cancer. J Clin Microbiol 2011;49(2):557–64.
[41] Cuzick J, Cadman L, Mesher D, et al. Comparing the performance of six human
papillomavirus tests in a screening population. Br J Cancer 2013;108(4):908–13.
[42] Iftner T, Becker S, Neis KJ, et al. Head-to-head comparison of the RNA-based
aptima human papillomavirus (HPV) assay and the DNA-based hybrid capture 2
HPV test in a routine screening population of women aged 30 to 60 years in Ger-
many. J Clin Microbiol 2015;53(8):2509–16.
[43] Baenke F, Peck B,Miess H, Schulze A. Hooked on fat: the role of lipid synthesis in cancer
metabolism and tumour development. Dis ModelMech 2013;6(6):1353–63.
[44] Long J, Zhang CJ, Zhu N, et al. Lipid metabolism and carcinogenesis, cancer devel-
opment. Am J Cancer Res 2018;8(5):778–91.
[45] Shimma S, Sugiura Y, Hayasaka T, Hoshikawa Y, Noda T, Setou M. MALDI-based
imaging mass spectrometry revealed abnormal distribution of phospholipids in
colon cancer liver metastasis. J Chromatogr B 2007;855(1):98–103.
[46] Beljebbar A, Dukic S, Amharref N, Bellefqih S, Manfait M. Monitoring of biochemi-
cal changes through the C6 gliomas progression and invasion by Fourier trans-
form infrared (FTIR) imaging. Anal Chem 2009;81(22):9247–56.
[47] Wang M, Wang C, Han RH, Han X. Novel advances in shotgun lipidomics for biol-
ogy and medicine. Prog Lipid Res 2016;61:83–108.
[48] Eberlin LS, Ferreira CR, Dill AL, Ifa DR, Cooks RG. Desorption electrospray ioniza-
tion mass spectrometry for lipid characterization and biological tissue imaging.
Biochim Biophys Acta-Mol Cell Biol L 2011;1811(11):946–60.
[49] Ilhan ZE, ºaniewski P, Thomas N, Roe DJ, Chase DM, Herbst-Kralovetz MM. Deci-
phering the complex interplay between microbiota, HPV, inflammation and can-
cer through cervicovaginal metabolic profiling. EBioMedicine 2019;44:675–90.
[50] Kriegsmann M, Wandernoth P, Lisenko K, et al. Detection of HPV subtypes by
mass spectrometry in FFPE tissue specimens: a reliable tool for routine diagnos-
tics. J Clin Pathol 2017;70(5):417–23.
[51] Lee JE, Lee S, Lee H, et al. Association of the vaginal microbiota with human papil-
lomavirus infection in a Korean twin cohort. PLoS ONE 2013;8(5).
[52] Gao W, Weng J, Gao Y, Chen X. Comparison of the vaginal microbiota diversity of
women with and without human papillomavirus infection: a cross-sectional
study. BMC Infect Dis 2013;13(1):271.
[53] Chen Y, Hong Z, Wang W, et al. Association between the vaginal microbiome and
high-risk human papillomavirus infection in pregnant Chinese women. BMC
Infect Dis 2019;19(1):677.
10 M. Paraskevaidi et al. / EBioMedicine 60 (2020) 103017[54] Boccardo E, Lepique AP, Villa LL. The role of inflammation in HPV carcinogenesis.
Carcinogenesis 2010;31(11):1905–12.
[55] Hung CY, Chao A, Wang C-C, et al. Glycerophospholipids and sphingoli-
pids correlate with poor prognostic genotypes of human papillomavirus
in cervical cancer: global lipidomics analysis. Anal Methods 2018;10
(41):4970–7.
[56] Ganova-Raeva LM, Khudyakov YE. Application of mass spectrometry to molecular
diagnostics of viral infections. Expert Rev Mol Diagn 2013;13(4):377–88.
[57] Ho YP, Reddy PM. Identification of Pathogens by Mass Spectrometry. Clin Chem
2010;56(4):525–36.
[58] S€oderlund-Strand A, Dillner J, Carlson J. High-throughput genotyping of onco-
genic human papilloma viruses with MALDI-TOF mass spectrometry. Clin Chem
2008;54(1):86–92.
[59] Cameron SJ, Bolt F, Perdones-Montero A, et al. Rapid evaporative ionisation mass
spectrometry (REIMS) provides accurate direct from culture species identification
within the genus Candida. Sci Rep 2016;6:36788.
[60] Bolt F, Cameron SJ, Karancsi T, et al. Automated high-throughput identifica-
tion and characterization of clinically important bacteria and fungi using
rapid evaporative ionization mass spectrometry. Anal Chem 2016;88
(19):9419–26.
[61] Arbyn M, Lion L, Yuill S, Gultekin M, Canfell K. ESGO meta-analysis: triage of HPV-
positive women. 21st Eur Congr Gynaecol Oncol 2019.
[62] Rijkaart DC, Berkhof J, Van Kemenade FJ, et al. Evaluation of 14 triage strategies
for HPV DNApositive women in populationbased cervical screening. Int J Can-
cer 2012;130(3):602–10.[63] Stanczuk GA, Baxter GJ, Currie H, et al. Defining optimal triage strategies for
hrHPV screenpositive women—an evaluation of HPV 16/18 genotyping, cytol-
ogy, and p16/Ki-67 cytoimmunochemistry. Cancer Epidemiol Biomarkers Prev
2017;26(11):1629–35.
[64] Arbyn M, Rezhake R, Yuill S, Canfell K. Triage of HPV-positive women in Norway
using cytology, HPV16/18 genotyping and HPV persistence. Br J Cancer 2020;122
(11):1577–9.
[65] Franco EL, Mahmud SM, Tota J, Ferenczy A, Coutlee F. The expected impact of HPV
vaccination on the accuracy of cervical cancer screening: the need for a paradigm
change. Arch Med Res 2009;40(6):478–85.
[66] Gajjar K, Ahmadzai AA, Valasoulis G, et al. Histology verification demonstrates
that biospectroscopy analysis of cervical cytology identifies underlying disease
more accurately than conventional screening: removing the confounder of dis-
cordance. PLoS ONE 2014;9(1):e82416.
[67] Duraipandian S, Traynor D, Kearney P, Martin C, O’Leary JJ, Lyng FM. Raman spec-
troscopic detection of high-grade cervical cytology: using morphologically nor-
mal appearing cells. Sci Rep 2018;8(1):1–8.
[68] Gu Y, Wu S-L, Meyer JL, et al. Proteomic analysis of high-grade dysplastic cervical
cells obtained from ThinPrep slides using laser capture microdissection and mass
spectrometry. J Proteome Res 2007;6(11):4256–68.
[69] Boylan KL, Afiuni-Zadeh S, Geller MA, et al. A feasibility study to identify proteins
in the residual Pap test fluid of women with normal cytology by mass spectrome-
try-based proteomics. Clin Proteomics 2014;11(1):30.
[70] Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet 2019;393
(10167):169–82.
